Promising US drug offers hope for pancreatic cancer patients

April 15, 2026 / 1:43 PM

Sharjah24 - WAM: US-based Revolution Medicines has announced that a new orally administered daily drug may represent a significant advance in the treatment of advanced pancreatic cancer. This follows clinical trial results showing improved survival rates compared to standard chemotherapy.

Improved survival outcomes

The company reported that the drug, daraxonrasib, reduced the risk of death by 60 percent among participants in a phase three clinical trial involving around 500 patients. It also reportedly doubled the average survival period.

Targeting cancer-driving mutations

According to the company, the drug works by targeting the RAS gene, mutations of which are linked to the development of several types of cancer.

Expert assessment

Brian Wolpin, the study’s principal investigator, said the approach represents a major medical advancement that could change clinical practice, particularly for patients whose cancer continues to progress despite chemotherapy.

Next regulatory steps

The company is expected to submit the trial data to the U.S. Food and Drug Administration for potential approval through a fast-track review process for promising treatments.